ROBOSENSE-LIDAR
29.7.2021 14:02:14 CEST | Business Wire | Press release
RoboSense LiDAR , the leading Smart LiDAR Sensor provider and GAC Aion New Energy Automobile Co., Ltd. (“GAC Aion”) set up by Guangzhou Automobile Group Co., Ltd (GAC Group，6601238.SH，02238.HK) , a Fortune 500 company and one of the automobile groups with the most complete industry chain in China jointly announced that GAC has selected RoboSense's second-generation intelligent solid-state LiDAR equipped with the ADiGO autonomous driving system，and will be mass-produced on a variety of autonomous driving models including the Aion LX of GAC Aion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005558/en/
ADiGO is an intelligent driving ecosystem led by GAC. This independently developed and interconnected ecosystem integrates smart factory, autopilot system, and IoT system. Powered by big data and various AI technologies, the self-driving system is available for mass production in L3 and is able to support L4 pilot running in some closed scenarios. The current ADiGO system on the Aion LX and Aion V uses a triple perception system (camera, millimeter wave radar, high-precision map) to achieve L3 autonomous driving in highway and urban expressway scenes.
The characteristics of Robosense's second-generation LiDAR active high-precision three-dimensional perception allows the ADiGO system to obtain more reliable perception information and ensure driving safety. It adopts a revolutionary two-dimensional MEMS smart chip scanning architecture and has a unique intelligent "GAZE" function, which can adjust the scanning method according to the driving scene, improve the perception of LiDAR, and help improve the performance and experience of autonomous driving. While achieving hardware intelligence verification, RS-LiDAR-Algorithm, the core of software intelligence, has more than 13-years of technology research and development accumulation. During the 5-year commercialization of LiDAR products, it has been verified by more than 100 partners in multiple scenarios around the world. Internally integrated AI perception algorithm, synchronously output 3D point cloud data and target-level environment perception results. The second-generation intelligent solid-state LiDAR helps the ADiGO system achieve a leap from safety to comfort in the driving experience under various road conditions.
In high-speed scenes, intelligent “GAZE” dynamically increases the vertical resolution of the ROI area, allowing the ADiGO system to find distant obstacles earlier, and enhance the autonomous driving experience on highways and urban expressways. In urban scenes, intelligent “GAZE” dynamically improves refresh the frame rate helps the ADiGO system respond more quickly to the dynamic changes of surrounding vehicles，pedestrians and other obstacles.
Due to technological innovation, the second-generation intelligent LiDAR can effectively control hardware costs, allowing more consumers to obtain a safer and more comfortable experience of autonomous driving. In the future, RoboSense will continue to promote technological innovation. Through the sustainable upgrad of intelligent LiDAR product system solution, it will work with partners to promote the intelligent car ecosystem.
About RoboSense (www.robosense.ai ):
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world leading provider of Smart LiDAR Sensor Systems. It incorporates LiDAR sensors, AI algorithms and IC chipsets that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. The company's mission is to produce outstanding hardware and artificial intelligence capabilities to provide smart solutions that enable robots (including vehicles) to have perception capability superior to humans.
About GAC Motor (https://www.gac-motor.com ):
Guangzhou Automobile Group Co., Ltd. (“GAC”) was incorporated in June 1997. In 2020, GAC’s production and sales both exceeded 2 million, with a positive year-on-year growth. Based on export planning, GAC Group successfully pushed ahead its international business, and GAC MOTOR was born with the right time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210729005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom